Lorcaserin 10 mg once daily (QD)

DRUG2 trials

Sponsors

Eisai Inc.

Conditions

Obesity

Phase 3

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

CompletedNCT00603902

Eisai Inc.Obesity

Start: 2008-01-31End: 2009-08-31Updated: 2019-10-04

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

CompletedNCT00603291

Eisai Inc.Obesity

Start: 2007-12-31End: 2010-10-31Updated: 2019-10-02

Related Papers

Lorcaserin and metabolic disease: weight‐loss dependent and independent effects

Obesity Science & Practice2018-08-076 citations

Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with ≥5% weight loss

Postgraduate Medicine2016-09-232 citations

Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders

Postgraduate Medicine2016-07-0715 citations

Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.

2016-05-178 citations

Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia

Postgraduate Medicine2016-04-2720 citations

Lorcaserin May Regulate Glucose Homeostasis Independent of Weight Loss

MD Conference Express2014-12-01

Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.

2013-05-0946 citations